Quantcast
Last updated on April 21, 2014 at 11:58 EDT

Latest Amikacin Stories

2012-08-02 02:31:33

MONMOUTH JUNCTION, N.J., Aug. 2, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent for ARIKACE(®) (liposomal amikacin for inhalation), U.S. Patent No. 8,226,975. Amikacin is one of the aminoglycosides covered by the patent. The patent describes a system for...

How To Create Antibiotics That Don't Hurt Hearing
2012-06-12 06:52:11

Apramycin, already used in animals, shows promise against drug-resistant TB and other 'superbugs,' without hearing loss The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria — but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells...

2012-06-11 10:24:04

Apramycin, already used in animals, shows promise against drug-resistant TB and other "superbugs", without hearing loss ANN ARBOR, Mich., June 11, 2012 /PRNewswire-USNewswire/ -- The world needs new antibiotics to overcome the ever-increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill...

2010-05-24 06:00:00

MONMOUTH JUNCTION, N.J., May 24 /PRNewswire/ -- Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE(TM) (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026. "The issuance of this composition of matter patent significantly...